Cargando…

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer

In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number of actionable targets is expanding, there is the need to timely detect their p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patelli, Giorgio, Mauri, Gianluca, Tosi, Federica, Amatu, Alessio, Bencardino, Katia, Bonazzina, Erica, Pizzutilo, Elio Gregory, Villa, Federica, Calvanese, Gabriele, Agostara, Alberto Giuseppe, Stabile, Stefano, Ghezzi, Silvia, Crisafulli, Giovanni, Di Nicolantonio, Federica, Marsoni, Silvia, Bardelli, Alberto, Siena, Salvatore, Sartore-Bianchi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643999/ https://www.ncbi.nlm.nih.gov/pubmed/37436743 http://dx.doi.org/10.1158/1078-0432.CCR-23-0079

Ejemplares similares

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature
por: Patelli, Giorgio, et al.
Publicado: (2021)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
por: Amatu, Alessio, et al.
Publicado: (2022)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
por: Lombardo, Roberta, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2021)

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
por: Patelli, Giorgio, et al.
Publicado: (2022)

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2017)

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
por: Durinikova, Erika, et al.
Publicado: (2022)

Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review
por: Gazzaniga, Gianluca, et al.
Publicado: (2022)

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
por: Rizzetto, Francesco, et al.
Publicado: (2020)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
por: Giannini, Valentina, et al.
Publicado: (2022)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
por: Amodio, Vito, et al.
Publicado: (2023)

Exploiting DNA repair defects in colorectal cancer
por: Reilly, Nicole M., et al.
Publicado: (2019)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
por: Russo, Mariangela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sejebv2eva0kp3cc767h0krjls